This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Clinical evaluation of haploidentical hematopoietic combined with human umbilical cord-derived mesenchymal stem cells in severe aplastic anemia
European Journal of Medical Research Open Access 01 March 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Farag SS . Chronic graft-versus-host disease. Bone Marrow Transplant 2004; 33: 569–577.
Stasi R, Stipa E, Forte V, Meo P, Amadori S . Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002; 99: 3872–3873.
Ratanatharathorn V, Carson E, Reynolds C, Ayash LJ, Levine J, Yanik G et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000; 133: 275–279.
Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003; 9: 505–511.
Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF . Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2005; 104: 2603–2606.
Liem LM, Fibbe WE, van Houwelingen HC, Goulmy E . Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation 1999; 15: 59–65.
Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E . Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients. Transplantation 1988; 46: 238–240.
Seaton ED, Szydlo RM, Kanfer E, Apperley JF, Russell-Jones R . Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood 2003; 102: 1217–1223.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Okamoto, M., Okano, A., Akamatsu, S. et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 20, 172–173 (2006). https://doi.org/10.1038/sj.leu.2403996
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403996
This article is cited by
-
Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide
Annals of Hematology (2021)
-
Safety and efficacy of rituximab-based first line treatment of chronic GVHD
Bone Marrow Transplantation (2019)
-
Clinical evaluation of haploidentical hematopoietic combined with human umbilical cord-derived mesenchymal stem cells in severe aplastic anemia
European Journal of Medical Research (2018)
-
Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD
Bone Marrow Transplantation (2016)
-
RETRACTED ARTICLE: Cotransplantation of human umbilical cord mesenchymal and haplo-hematopoietic stem cells in patients with severe aplastic anemia
Cytotechnology (2016)